You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Suppliers and packagers for paxil


✉ Email this page to a colleague

« Back to Dashboard


paxil

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Apotex PAXIL paroxetine hydrochloride TABLET;ORAL 020031 NDA Apotex Corp 60505-4517-3 30 TABLET, FILM COATED in 1 BOTTLE (60505-4517-3) 2019-03-11
Apotex PAXIL paroxetine hydrochloride TABLET;ORAL 020031 NDA Apotex Corp 60505-4518-3 30 TABLET, FILM COATED in 1 BOTTLE (60505-4518-3) 2019-03-11
Apotex PAXIL paroxetine hydrochloride TABLET;ORAL 020031 NDA Apotex Corp 60505-4519-3 30 TABLET, FILM COATED in 1 BOTTLE (60505-4519-3) 2019-03-11
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Last updated: July 29, 2025

ppliers for the Pharmaceutical Drug: Paxil

Introduction
Paxil, known chemically as paroxetine, is a selective serotonin reuptake inhibitor (SSRI) widely prescribed for depression, anxiety disorders, obsessive-compulsive disorder, and other psychiatric conditions. Since its initial approval by the U.S. Food and Drug Administration (FDA) in 1992, Paxil has seen widespread use, necessitating a complex supply chain involving multiple suppliers across various stages of manufacturing. This article provides an in-depth overview of the key suppliers involved in Paxil's production, the sourcing of active pharmaceutical ingredients (APIs), excipients, and finished formulations, and the implications for stakeholders within the pharmaceutical supply chain.


Active Pharmaceutical Ingredient (API) Suppliers

1. Chemical Synthesis of Paroxetine API
The cornerstone of Paxil's production lies in sourcing high-purity paroxetine API. Leading pharmaceutical conglomerates and specialized chemical manufacturers globally supply this API. Notable API manufacturers include Siegfried, based in Switzerland, and Hikal Limited in India. Both companies employ sophisticated chemical synthesis techniques, ensuring compliance with Good Manufacturing Practices (GMP), and hold regulatory approvals from agencies such as the FDA, EMA, and other regional authorities. These firms supply bulk API to pharmaceutical companies and contract manufacturers (CMOs) involved in Paxil's formulation.

2. Contract Manufacturers and API Blenders
Numerous CMO firms, especially in Asia-Pacific, procure API from primary suppliers for final formulation and packaging. Chinese and Indian manufacturers dominate global API production, leveraging cost efficiencies and established chemical manufacturing infrastructure. Companies like Sun Pharmaceutical Industries and Dr. Reddy's Laboratories in India are recognized for their API manufacturing capabilities, including paroxetine. These suppliers often operate under strict quality controls to meet international standards and are certified for export to North America and Europe.

3. Supply Chain Dynamics and Regulatory Oversight
The supply chain's complexity involves multiple tiers, with some APIs produced in regions with less stringent regulatory oversight, increasing risks related to quality and supply continuity. Recent initiatives, such as the U.S. FDA's Drug Supply Chain Security Act (DSCSA) and the European Medicines Agency (EMA) regulations, aim to enhance traceability and integrity across API sourcing.


Excipients and Formulation Components Suppliers

1. Excipients Essential for Paxil Formulation
In addition to API sourcing, excipients—including fillers, binders, disintegrants, and stabilizers—are critical to Paxil's final pharmaceutical form. Major excipient suppliers include global giants like Jubilant Life Sciences, Roquette, and Colorcon. These companies provide inactivated ingredients such as microcrystalline cellulose, lactose, povidone, and magnesium stearate, used in tablet manufacturing.

2. Packaging Materials
Packaging suppliers, such as Gerresheimer and Schott AG, supply blister packs, bottles, and labeling materials that meet regulatory standards for pharmaceutical packaging. Accurate serialization and tamper-proof packaging are vital for Paxil's distribution, especially given the medication's potential for misuse and off-label dispensing.


Final Drug Formulation and Distribution

1. Contract Manufacturing Organizations (CMOs)
Multinational pharmaceutical firms often partner with CMOs to produce Paxil at scale, ensuring regulatory compliance and maintaining quality standards. Notable CMOs include Catalent, Lonza, and Alcami, which offer comprehensive manufacturing, fill-finish, and packaging services. These organizations play a pivotal role in ensuring supply chain resilience, especially during global disruptions such as the COVID-19 pandemic.

2. Distributors and Wholesalers
Once manufactured, Paxil products are distributed through a network of wholesalers and distributors to pharmacies, hospitals, and healthcare providers worldwide. Key global distributors include McKesson, AmerisourceBergen, and Cardinal Health. Their supply chains are highly interconnected, requiring real-time inventory tracking and compliance with regulations like the Drug Supply Chain Security Act (DSCSA).


Global Supply Chain Risks and Regulatory Factors

1. Geopolitical and Economic Challenges
The global API supply chain for Paxil faces geopolitical challenges, trade tensions, and export restrictions which impact ingredient availability. For example, U.S. dependency on Indian and Chinese API manufacturing underscores vulnerability in supply continuity.

2. Regulatory Compliance and Quality Assurance
Suppliers must adhere to stringent GMP standards mandated by the FDA, EMA, and other jurisdictions. Certification processes, routine inspections, and batch testing ensure API quality, critical for patient safety and efficacy. Regulatory non-compliance or contamination incidents can disrupt supply chains and erode trust.

3. Market Dynamics and Cost Pressures
Price pressures influence procurement strategies, leading pharmaceutical companies to diversify supplier bases and seek cost-effective alternatives. However, balancing cost with quality remains paramount, especially for mental health medications like Paxil, where therapeutic efficacy depends on raw material integrity.


Key Suppliers Summary

Supplier Type Example Companies Role & Contribution Geographic Focus Regulatory Certification
API Manufacturers Siegfried, Hikal Limited, Sun Pharma, Dr. Reddy's Supply high-purity paroxetine API Switzerland, India, China FDA, EMA GMP
Excipients Suppliers Jubilant Life Sciences, Roquette, Colorcon Provide excipients for formulation India, France, US GMP, ISO
Packaging Suppliers Gerresheimer, Schott AG Supply blister packs, bottles, labeling Germany, US GMP, ISO
Contract Manufacturers & CMOs Catalent, Lonza, Alcami Final formulation, packaging US, Europe, Asia cGMP
Distributors McKesson, AmerisourceBergen, Cardinal Health Distribution network Global DSCSA compliance

Conclusion

The Paxil supply chain exemplifies the interconnectedness of global pharmaceutical manufacturing, involving numerous tiers of suppliers—from chemical synthesis in Asia and Europe to formulation by contract organizations, and distribution worldwide. Ensuring transparency, compliance, and supply security remains a priority for stakeholders, given the medication's widespread use and sensitive nature. Companies sourcing Paxil must navigate geopolitical risks, adhere to rigorous regulatory standards, and foster resilient supplier relationships to maintain uninterrupted drug availability.


Key Takeaways

  • Diverse, global API sourcing from certified suppliers like Siegfried and Hikal ensures supply continuity and quality.
  • Regulatory compliance remains critical across all supply chain tiers, influencing procurement choices and risk management.
  • Asian manufacturers dominate API production, underscoring the importance of oversight and quality assurance.
  • Supply chain resilience depends on diversified sourcing, robust partnerships with CMOs, and adherence to global standards.
  • Geopolitical and trade uncertainties necessitate strategic planning and contingency measures.

FAQs

1. Who are the main API suppliers for Paxil?
Leading API suppliers include Siegfried (Switzerland), Hikal Limited (India), Sun Pharma, and Dr. Reddy's Laboratories (India). These companies produce high-quality paroxetine raw material for global markets.

2. How does regulatory oversight impact Paxil's supply chain?
Regulatory bodies like the FDA and EMA enforce GMP standards, requiring suppliers to maintain strict quality controls, which affects sourcing, manufacturing, and distribution practices. Non-compliance can lead to supply disruptions.

3. Are Chinese and Indian manufacturers reliable for Paxil's API supply?
Yes, many Chinese and Indian companies hold international GMP certifications and supply significant portions of the global API market, including for Paxil. However, ongoing oversight and quality assurance are essential.

4. What risks threaten the Paxil supply chain?
Risks include geopolitical tensions, export restrictions, quality failures, supply chain disruptions due to pandemics, and regulatory changes. Diversification and quality assurance mitigate these threats.

5. How can companies improve supply chain resilience for Paxil?
By diversifying sourcing, establishing relationships with multiple certified suppliers, implementing rigorous quality controls, and staying abreast of geopolitical and regulatory developments.


Sources
[1] U.S. Food and Drug Administration. (2022). FDA Guidance on API Manufacturing.
[2] European Medicines Agency. (2021). Guidelines on Good Manufacturing Practice.
[3] IQVIA. (2022). Global Pharmaceutical Market Analysis.
[4] Pharmaceutical Technology. (2021). API Supply Chain Challenges and Opportunities.
[5] U.S. DSCSA Implementation. (2022). Supply Chain Security Standards.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.